Press Releases Lunit Inc.

Equities

A328130

KR7328130000

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-23 EDT			5-day change	1st Jan Change
45,000 ^KRW	-2.81%		-9.27%	-45.05%

05-31	Lunit Inc. announced that it has received KRW 171.5 billion in funding from a group of investors	CI
05-24	Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients	03-27	AQ
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment, New Study in Breast Cancer Research	03-15	AQ
Lunit Presents Seven Study Results at ECR 2024, Showcasing AI's Robust Performance in Diverse Clinical Settings	02-29	AQ
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy across Diverse Tumors, published in the JITC	02-19	AQ
Lunit INSIGHT CXR Excels in Long Nodule Detection, Exceptional Performance in Head-to-Head Study published in Radiology	01-18	AQ
Lunit to Acquire Volpara, Scheme Implementation Agreement Signed	12-15	AQ
Lunit Advances to Stage 2 of Australia s National Breast Cancer Screening Project	12-12	AQ
Lunit Secures $150 Million in Capital Increase	11-16	AQ
Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT	11-15	AQ
Lunit Participates in Saudi Vision 2030 Healthcare Sandbox, Accelerating Saudi Arabia's Healthcare Transformation	23-10-27	AQ
First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO, newly published in JCO	23-10-25	AQ
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes, Findings to be presented at the ESMO 2023	23-10-17	AQ
Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment to be presented at WCLC 2023	23-08-22	AQ
Lunit and the Japan National Cancer Center Hospital East Partner in AI Pathology to Advance Precision Oncology	23-05-31	AQ
Guardant Health introduces Guardant Galaxy suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery	23-02-01	AQ
Top Artificial Intelligence Trends Influencing the Future of Radiology	22-08-12	AQ
NVIDIA -Shifting Into High Gear: Lunit, Maker of FDA-Cleared AI for Cancer Analysis, Goes Public in Seoul	22-07-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer